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RESUMO – O vemurafenib, um inibidor seletivo da mutação BRAF V600, está aprovado pela Food and Drug Administration 
(FDA) e European Medicines Agency (EMA) para o tratamento de melanoma metastático em estadio IV isoladamente ou em 
combinação. De entre os efeitos adversos, a toxicidade cutânea é a mais comum. A maior parte destas reações, como o erite-
ma, a fotossensibilidade e as lesões hiperqueratósicas, são facilmente controladas podendo a maioria dos doentes continuar 
terapêutica. Contudo, têm sido descritos alguns casos de reações cutâneas graves com risco de vida e necessidade de suspen-
são terapêutica. Os autores reportam um caso de necrólise epidérmica tóxica induzida pelo vemurafenib num doente a efetuar 
tratamento para melanoma metastizado. Após várias complicações hospitalares, o doente sobreviveu à reação provocada pelo 
fármaco e encontra-se em remissão há 2 anos.  
PALAVRAS-CHAVE – Antineoplásicos/efeitos adversos; Melanoma/tratamento; Síndrome de Stevens-Johnson/etiologia; Ve-
murafenib.
Vemurafenib-Induced Toxic Epidermal Necrolysis: An 
Emerging Adverse Event
ABSTRACT – Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medici-
nes Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cuta-
neous toxicity is the most common. Most of these reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions 
are manageable, and the majority of patients are able to continue therapy. However, a few cases of life-threatening severe cutaneous 
adverse reactions have been reported and drug withdrawal is mandatory in these cases. Herein, we report a case of vemurafenib-
-induced toxic epidermal necrolysis in a patient receiving therapy for metastatic melanoma. After several hospital complications, our 
patient survived to the drug-induced reaction and he is in remission for 2 years. 
KEYWORDS – Antineoplastic Agents/adverse effects; Melanoma/drug therapy; Stevens-Johnson Syndrome/etiology; Vemurafenib.
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INTRODUCTION 
The selective BRAF inhibitor vemurafenib was approved 
by the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for the treatment of metastatic or 
unresectable melanoma with BRAF V600 mutation. It sig-
nificantly increases the response rate, prolonged progres-
sion-free and overall survival in melanoma patients with 
BRAF mutation.1 Initially it was approved as monothera-
py, nowadays it is used in combination with a MEK inhi-
bitor. However, the promising efficacy of this drug needs 
to be considered against the potential adverse side effects 
during treatment. Drug-induced skin reactions are well 
known common side effects of vemurafenib therapy, in-
cluding skin rash, phototoxicity and keratotic hyperproli-
ferative lesions.2 Most of these reactions are manageable, 
and the majority of patients are able to continue therapy. 
However, more serious adverse reactions (grade 4) are ra-
rely described in literature and require drug suspension 
limiting the use of vemurafenib.
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CASE REPORT
A 47-year-old man was diagnosed with superficial sprea-
ding left lumbar melanoma (Breslow thickness 2,15 mm, 
without ulceration, Clark level III) in May 2008 and positive 
sentinel lymph node biopsy. He underwent left inguinal lym-
phadenectomy for micrometastasis (1N+/7N). There was no 
relevant past history or medication use. The complete com-
puted tomography scan (CT-scan) did not show any suspec-
ted metastatic lesions. The patient was staged as T3aN1aM0 
and interferon alpha-2b (10MU three times per week) was 
administered subcutaneously during 1 year. Five years later, 
he presented with in-transit metastases in the left flank and 
iliac fossa that were excised. The complete CT-scan also re-
vealed three new micronodules (< 5 mm) in the right lower 
lobe and two micronodules in the left upper lobe of the lung. 
These new findings were considered metastatic lesions, al-
though histological confirmation was not possible due to 
their small size. Mutation analysis (cobas® 4800 BRAF V600 
Mutation Test; Roche Diagnostics Limited) of a metastatic sub-
cutaneous node showed a BRAF V600E mutation, and the 
patient was offered vemurafenib 960 mg twice daily. Serum 
lactate dehydrogenase level at this time was 171 U/L (normal 
range 125-220).
Eight days later, the patient developed a grade 2 macu-
lopapular rash (Common Terminology Criteria for Adverse 
Events version 4.0 of the National Cancer Institute), initially 
restricted to lower limbs, associated to high fever (39.3º) and 
pruritus. During the following three days, the skin lesions pro-
gressed to widespread erythema with blisters involving head, 
trunk, arms and limbs (Fig. 1). Bilateral conjunctivitis, large 
erosions and ulceration of the oral mucosa were observed 
(Fig. 2). Laboratory investigations showed just a mild increa-
se in liver aminotransferases (two times normal). The pa-
tient denied taking any other drugs. On clinical assessment, 
SCORTEN (SCORe of Toxic Epidermal Necrolysis) was calcu-
lated as 3, predicting a mortality rate of > 35%. The ALDEN 
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Figure 1 - Erythema with blistering and epidermal detachment involving the trunk (A,B). Skin lesions progressed to widespread erythema with blisters 
involving arms and limbs (C, D).
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(ALgorithm of Drug causality for Epidermal Necrolysis) score 
for vemurafenib was calculated as 5 (probable) and Naranjo 
score as 6 (probable). Vemurafenib was withdrawn, suppor-
tive treatment with prednisolone 1 mg/kg/day was started 
and he was immediately transferred to an intensive care unit. 
During the next 72 hours, lesions progressed to affect 90% 
of total body surface and mucosal sloughing in the upper 
airway. Intravenous immunoglobulin (IV Ig) was started at 
the dose of 1.5 mg/kg over 3 days. Re-epithelialization was 
slow, and therefore further 3 days of IV Ig at the same dose 
were prescribed. After 2 months of multiple complications in 
the intensive care unit, the patient was transferred back to the 
dermatology ward.
After this episode the patient has been submitted to a 
continuous follow-up. The patient has been on clinical and 
radiological remission. The complete CT-scan one and two 
years after the episode showed lung parenchyma without 
new lesions and no increase of the lung micronodules in 
comparison to the first CT-scan. 
DISCUSSION 
Vemurafenib is a selective inhibitor of the BRAF V600 muta-
tion approved for stage IV metastatic melanoma.1 Among the 
adverse effects, cutaneous toxicity is the most common, affec-
ting more than 90% of patients.2 It is rarely severe, with 15% - 
40% of grade 3 and less than 1% of grade 4 toxicities reported 
in literature.1,3 Skin rash induced by vemurafenib was the most 
commonly reported adverse effect with a frequency in clinical 
trials ranging from 36% to 68%.2,4 Skin rash usually occurred 
on the face, neck, trunk, and extremities and appeared with a 
mean time of 1.6 weeks after vemurafenib treatment.2 Howe-
ver, serious cutaneous adverse events such as Stevens-John-
son syndrome, toxic epidermal necrolysis (TEN), cellulitis, drug 
reaction with eosinophilia and systemic symptoms (DRESS) are 
rare and a mandatory condition to drug discontinuation.2
Although a rare reaction in clinical practice, TEN has alrea-
dy been described in BRIM-3 study.5 In the literature, toxic epi-
dermal necrolysis due to vemurafenib was described in 6 case 
reports in the last 4 years (Table 1).6-11 Some authors believe 
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Figure 2 - Widespread erythema of the face with bilateral conjunctivitis (A). Cheilitis, large erosions and ulceration of the lips and tongue (B).
A B
Table 1 - Summary of the characteristics of cases reported in the literature with TEN after vemurafenib.
Case Year Gender Age
Onset of rash 
(days after star-
ting vemurafenib)
Treatment 
performed for TEN
Other Melanoma 
therapy before 
vemurafenib
Evolution / Follow 
up
Wantz et al8 2013 F 75 21
Systemic 
corticotherapy
No
Died of disease 
progression
Sinha et al6 2014 F 73 15
Intravenous 
immunoglobulin
Not mentioned
Died of multiorgan 
failure
Jeudy et al7 2015 M 60 10 Not mentioned Interferon alpha-2b Switch to dabrafenib
Lapresta et al9 2015 M 68 28
Intravenous 
ciclosporin
No Switch to ipilimumab
Arenbergerova 
et al10
2017 F 63 10
Intravenous 
corticotherapy
Nivolumab
Died of disease 
progression
Kılıç et al11 2017 M 69 15
Intravenous 
corticotherapy + 
immunoglobulin
Interferon alpha-2b Died of sepsis
Our case 2017 M 47 8
Intravenous 
corticotherapy + 
immunoglobulin
Interferon alpha-
-2b
Complete remis-
sion
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that immune checkpoint inhibition by ipilimumab or nivolu-
mab may predispose patients to drug hypersensitivity reactions 
due to strong activation of CD8+ cells.10 Concerning interferon 
alpha, it has been associated with a transient and mild ge-
neralized rash-like reaction but there is no severe cutaneous 
reactions reported.12,13 Nevertheless, our case occurred from 
the isolated use of vemurafenib without previous checkpoint 
inhibitor drugs.
This case highlights the importance of careful patient moni-
toring, with particular attention to the development of skin rash 
with signs of severity within 2 weeks after vemurafenib initia-
tion, such as epidermal detachment or mucosal involvement.3 
Furthermore, a recent retrospective cohort study has shown 
for the first time a significant increase in overall survival in 
patients with severe toxicity emerging within the first 4 and 8 
weeks on vemurafenib.3 An explanation could be that the cuta-
neous drug reaction severity is the result of a strong activa-
tion of the innate immunity inducing a synergistic effect with 
vemurafenib against melanoma cells. However, this statement 
has to be confirmed in further studies with larger cohorts of 
patients. Fortunately, our patient survived to the drug-induced 
reaction and he did not present new in-transit metastasis since 
the drug reaction. He is in clinical and radiological remission 
for 3 years. If there is a future disease progression, drug swi-
tching to dabrafenib and trametinib appears to be a useful 
alternative treatment option.7
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